Moleculin reports 43% and 36% complete remission rates in Annamycin Phase 2/3 trial for relapsed/refractory AML

Moleculin Biotech reported 43% and 36% complete remission rates in its Annamycin Phase 2/3 trial for relapsed or refractory acute myeloid leukemia.

Detected & updated continuously · Source: Nebula